ClinicalTrials.Veeva

Menu
H

Health Concepts | Rapid City, SD

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Dupilumab
PF-04965842
Relamorelin
Olezarsen
PF-06700841
Tanezumab
Hydrocodone Bitartrate
Amlitelimab
K-877
JNJ-77242113

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

22 of 100 total trials

A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy (REGAiN-1B)

To evaluate the durability of efficacy and long-term safety of intramuscular (IM) administration of Engensis or Placebo that was administered in the...

Enrolling
Diabetic Peripheral Neuropathy
Other: Placebo
Biological: Engensis

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo
Locations recently updated

The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type...

Enrolling
Type 2 Diabetes (T2D)
Drug: Placebo (NNC0487-0111 oral)
Drug: NNC0487-0111 oral

The coprimary objectives of the study are to:* evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcin...

Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Active, not recruiting
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

Enrolling
Severe Hypertriglyceridemia
Drug: Olezarsen

The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from bas...

Active, not recruiting
Severe Hypertriglyceridemia
Drug: Olezarsen
Drug: Placebo

The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in particip...

Active, not recruiting
Hypertriglyceridemia
Cardiovascular Diseases
Drug: Placebo
Drug: Olezarsen

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

This is a parallel, Phase 2 multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study to investigate the efficacy and saf...

Enrolling
Alopecia Areata
Drug: Placebo
Drug: Amlitelimab

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm monotherapy study for treatment of...

Enrolling
Dermatitis Atopic
Drug: Placebo
Drug: Amlitelimab

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Enrolling
Alopecia Areata
Drug: Upadacitinib
Drug: Placebo

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 yea...

Enrolling
Dermatitis Atopic
Drug: Placebo
Drug: Amlitelimab

Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and a...

Enrolling
Moderate Plaque Psoriasis
Drug: Risankizumab
Drug: Deucravacitinib

The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneous using devices for injection at home.

Enrolling
Atopic Dermatitis
Combination Product: Rocatinlimab AI
Combination Product: Rocatinlimab Prefilled Syringe

A double-blind, randomized, placebo-controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of single injection of...

Active, not recruiting
Osteoarthritis
Drug: RTX-GRT7039
Drug: Placebo

This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to e...

Enrolling
Alzheimer Disease
Drug: Placebo
Drug: AR1001

Primary Objective:To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Inhaled Long-Acting Muscarinic Antagonist

This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to...

Enrolling
Asthma
Drug: Placebo
Drug: Dupilumab

Trial sponsors

Pfizer logo
AbbVie logo
Sanofi logo
Allergan logo
Ionis Pharmaceuticals logo
Janssen (J&J Innovative Medicine) logo
Amgen logo
B
Boehringer Ingelheim logo
Bristol-Myers Squibb (BMS) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems